INSMED Inc
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $425.50M | $-0.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $306.00M | $-0.76 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | Before market open | $263.80M | $-1.54 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $107.40M | $-1.70 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $92.80M | $-1.42 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | Before market open | $104.40M | $-1.32 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $93.40M | $-1.27 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $90.30M | $-1.94 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| BRINSUPRI revenues | full-year 2026 | $1.25B to $1.40B | Raised |
| ARIKAYCE revenues | full-year 2026 | $450.00M to $470.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Insmed filed with the SEC
— Sara Bonstein Will Step
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
August 6, 2026 Second-Quarter 2026 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
July 16, 2026 12-Month Results from Ongoing Open-Label Extension Study of TPIP in
Regulation FD disclosure · EX-99.2 to Form 8-K
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
May 7, 2026 First-Quarter 2026 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K
Insmed Provides Clinical Update on Phase 2b CEDAR Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE ® (Amikacin Liposome Inhalation Suspension) in Patients with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
March 23, 2026 Topline Results of Phase 3b ENCORE Study of ARIKAYCE® in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
February 19, 2026 Fourth-Quarter 2025 Earnings Presentation
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
January 12, 2026 J.P. Morgan Healthcare Conference Presentation
Regulation FD disclosure · EX-99.2 to Form 8-K
Insmed Provides Clinical and Business Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
October 30, 2025 Third-Quarter 2025 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
August 7, 2025 Second-Quarter 2025 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K
Insmed Announces Proposed $650 Million Public Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
June 10, 2025 Topline Results of Phase 2b Study of TPIP in PAH Patients TPIP:
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
May 8, 2025 First-Quarter 2025 Earnings Presentation
Results of operations · EX-99.2 to Form 8-K
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
Other events · EX-99.1 to Form 8-K
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Forward Looking Statements This presentation contains forward-looking
Results of operations · Executive or director change · EX-99.2 to Form 8-K
FDA Grants Priority Review to Insmed’s Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
January 13, 2025 JPMorgan Healthcare Conference Presentation
Regulation FD disclosure · EX-99.2 to Form 8-K
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Regulation FD disclosure · EX-99.2 to Form 8-K
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
Other events · EX-99.1 to Form 8-K